The FDA has approved the rotigotine transdermal system (Neupro, UCB) for signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and for treating moderate-to-severe primary restless legs syndrome, or RLS. The drug was previously approved for early stage idiopathic PD.
Abstract: UCB.
